四联药物治疗幽门螺杆菌感染慢性胃炎安全性及疗效分析  

Quadruple drugs therapy in treatment of chronic gastritis with Helicobacter pylori infection: an analysis of safety and efficacy

作　　者：杨潇[1] 吕燕娜[2] 

机构地区：[1]四川省峨眉山市人民医院消化内科,614200 [2]四川省乐山市人民医院综合内科,614200

出　　处：《淮海医药》2017年第3期272-273,共2页Journal of Huaihai Medicine

摘　　要：目的:分析四联药物治疗幽门螺杆菌感染慢性胃炎安全性及疗效。方法:将150例幽门螺杆菌感染慢性胃炎患者按治疗方法不同分为A,B,C 3组。均给予雷贝拉唑、胶体铋剂、克拉霉素。A组另增加阿莫西林,B组另增加甲硝唑。比较3组治疗总有效率、症状及溃疡消失率、幽门螺杆菌清除率。观察不良反应。结果:A组治疗总有效率(92.00%)最高,B组(86.00%)高于C组;A组消化道症状消失率(90.00%)、溃疡消失率(94.00%)以及幽门螺杆菌根除率(92.00%)均为最高,B组高于C组(P<0.05)。均无明显不良反应。结论:四联药物治疗幽门螺杆菌疗效较三联药物疗效强,无明显不良反应,含铋剂四联疗法中阿莫西林的效果较甲硝唑优。Objective： To analyze the safety and efficacy of treatment of chronic gastritis with Helicobacter pylori infection by quadiuple drugs therapy. Methods：IS0 cases of chronic gastritis patients with Helicobacter pylori infection were divided into 3 groups according to treatment methods. Rebela, colloidal bismuth agent, and clarithromycin were administered to the 3 groups. On the basis of the medication, group A was added with amoxicillin and group B with metronidazole. Comparison was conducted in terms of the total effective rate, disappearance rate of symptoms and ulcer, and eradication rate of Helieobacter pylori. Meanwhile p adverse reactions were observed. Results：The total effective rate of group A （92%） , and group B （86%） was higher than that of group C. As for group A, the gastrointestinal symptoms disappearance rate （ 90% ）, the ulcer disappearance rate （ 94% ） and Helicobacter pylori eradication rate （ 92% ） were the highest among the 3 groups, and group B was higher than group C in terms of the rates （ P 〈 0.05 ）. No obvious adverse reactions occurred in the 3 groups. Conclusion：Quadruple drugs therapy in treatment of Helicobacter pylori infection is more effective than triple drugs therapy. No obvious adverse reactions are observed.

关 键 词：胃炎 幽门螺杆菌 四联药物 阿莫西林 

分 类 号：R573.3[医药卫生—消化系统]